SCHEMBL19711151

SCHEMBL19711151

CC(=O)N1CCC(c2cccc(C)c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QDPR P09417 2/20 0.61
MCHR1 Q99705 1/20 0.56
HTR2C P28335 2/20 0.53
ADAM17 P78536 1/20 0.51
ADAMTS5 Q9UNA0 1/20 0.51
LIPE Q05469 1/20 0.50
ADAM10 O14672 1/20 0.49
MMP2 P08253 1/20 0.49
MMP9 P14780 1/20 0.49
NPC1 O15118 1/20 0.49
TP53 P04637 1/20 0.49
MAPT P10636 1/20 0.49
RAB9A P51151 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
SOS1 Q07889 1/20 0.48
DRD4 P21917 5/20 0.48
DRD2 P14416 4/20 0.48
DRD3 P35462 3/20 0.48
USP5 P45974 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16785547 0.91 NPC1 (0.56) QDPRMCHR1HTR2CADAM17ADAMTS5
SCHEMBL7482001 0.84 QDPR (0.66) QDPRDRD4DRD2DRD3DRD1
SCHEMBL19658654 0.83 QDPR (0.60) QDPRADAMTS5LIPENPC1DRD4
SCHEMBL2651932 0.83 QDPR (0.60) QDPRMCHR1SOS1
SCHEMBL1091809 0.83 QDPR (0.60) QDPRMCHR1TP53DRD4DRD2
SCHEMBL1473424 0.82 QDPR (0.61) QDPRNPC1TP53RAB9ASMN1; SMN2
SCHEMBL14590572 0.81 QDPR (0.61) QDPRHTR2CDRD2USP5
SCHEMBL27304673 0.81 QDPR (0.69) QDPRMCHR1LIPEDRD2
SCHEMBL5670914 0.81 QDPR (0.57) QDPRLIPEADAM10MMP2SOS1
SCHEMBL30563607 0.80 GPR119 (0.65) TP53MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3209664-B1 BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-06-03 EP disclosed
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS PIK3R3, JAK2, JAK3 QDPR 2037/4885MCHR1 3120/4885HTR2C 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.